ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: PP07

Remissions and Vigilance

Michael Scepaniak, Cockeysville, MD

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), Patient reported outcomes, prevention, spondyloarthritis, Therapy, alternative

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Patient Perspectives Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: I’ve been diagnosed with spondyloarthritis (SpA) for a little more than 7 1/2 years. That diagnosis was preceded by roughly 9 months of significant disease activity, which in turn was preceded by a decade of “introductory” back and hip pain. Once diagnosed, I started a regimen of nonsteroidal anti-inflammatory drugs (NSAIDs). With them, came relief, and then (after a year or so) remission, and then no more drugs.

At that point, I was 40 years old. I’m now 47. The intervening 7 years have been anything but disease-free.

Intervention: Because of my SpA, I’ve had localized, transitory inflammatory pain all over my body – shoulders, hips, back (upper, middle, and lower), feet, ankles, knees, neck, and chest. When warranted (by the pain), my go-to option has been NSAIDs. But, the stubborn guy that I am, I’ve always fought my way off of them.

At various points, my doctors have encouraged me to take biologics, which I have respectfully declined. Instead, I’ve experimented with a plethora of alternative treatments and lifestyle changes, including:

– Health journaling
– Taking cold showers
– Sleeping on the floor
– Fasting, both intermittent and multi-day
– Daily stretching and self-massage
– Focusing on breathing through my nose
– Eating a paleo diet
– Running errands via bicycle
– Slacklining
– Meditative breathing

The result? Three remissions. Which treatment(s)/change(s) get(s) credit? Hard to say. But, because a lot of the experiments I undertake seem worthwhile to me, I continue on with them – SpA or not.

For me, vigilance is key. I continually channel my efforts at preventative health and conditioning. I push ahead when my symptoms allow. By establishing higher expectations of my body and for myself, as I am able, I increase the degree to which I can degrade during periods of disease activity. Instead of regarding my SpA as ever being in remission, I always prefer thinking of it as being temporarily inactive, or quiet. I continue in a manner that basically presumes that my remission is not permanent.

Maintenance: Here are my totals:

– Seven and a half years since diagnosis
– Five and a half years of disease activity
– Two and a half years of disease inactivity
– Just under 2 years of taking medications (NSAIDs)
– 3 remissions

Quality of Life: SpA does not limit what I do in life. However, the mindset I’ve taken is that I will never be completely free of it. My goal is to extend my periods of disease inactivity for as long as I can. Whenever my disease becomes more active, I’ll work to quiet it as quickly as possible. My eventual goal is to get to the point where, overall, my disease is more quiet than active.

Supporting image 1

Michael Scepaniak walking on a slackline, Summer 2018.

Supporting image 2

Michael Scepaniak departing from a local farmers’ market on his bicycle, Summer 2020.


Disclosures: M. Scepaniak, Viome.

To cite this abstract in AMA style:

Scepaniak M. Remissions and Vigilance [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/remissions-and-vigilance/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/remissions-and-vigilance/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology